- Home
- CWEN vs CRNX Comparison
CWEN vs CRNX Comparison
Compare CWEN & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- CRNX
- Stock Information
- Founded
- CWEN 2012
- CRNX 2008
- Country
- CWEN United States
- CRNX United States
- Employees
- CWEN N/A
- CRNX 437
- Industry
- CWEN Electric Utilities: Central
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- CWEN Utilities
- CRNX Health Care
- Exchange
- CWEN Nasdaq
- CRNX Nasdaq
- Market Cap
- CWEN 3.4B
- CRNX 2.8B
- IPO Year
- CWEN 2013
- CRNX 2018
- Fundamental
- Price
- CWEN $30.36
- CRNX $31.88
- Analyst Decision
- CWEN Strong Buy
- CRNX Strong Buy
- Analyst Count
- CWEN 4
- CRNX 10
- Target Price
- CWEN $35.75
- CRNX $75.00
- AVG Volume (30 Days)
- CWEN 863.2K
- CRNX 942.0K
- Earning Date
- CWEN 04-30-2025
- CRNX 05-08-2025
- Dividend Yield
- CWEN 5.64%
- CRNX N/A
- EPS Growth
- CWEN 20.79
- CRNX N/A
- EPS
- CWEN 0.79
- CRNX N/A
- Revenue
- CWEN $1,406,000,000.00
- CRNX $760,000.00
- Revenue This Year
- CWEN $7.88
- CRNX $343.70
- Revenue Next Year
- CWEN $10.82
- CRNX $733.93
- P/E Ratio
- CWEN $38.17
- CRNX N/A
- Revenue Growth
- CWEN 9.08
- CRNX N/A
- 52 Week Low
- CWEN $24.02
- CRNX $24.10
- 52 Week High
- CWEN $31.09
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- CWEN 55.75
- CRNX 53.86
- Support Level
- CWEN $30.13
- CRNX $29.22
- Resistance Level
- CWEN $31.02
- CRNX $30.99
- Average True Range (ATR)
- CWEN 0.69
- CRNX 1.40
- MACD
- CWEN 0.06
- CRNX 0.04
- Stochastic Oscillator
- CWEN 74.90
- CRNX 64.17
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.